Benzazepinone alpha vintegrin receptor antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C540S523000

Reexamination Certificate

active

07109191

ABSTRACT:
The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and αvβ5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

REFERENCES:
patent: 6232308 (2001-05-01), Askew
patent: 6825188 (2004-11-01), Callahan et al.
patent: WO 98/14192 (1998-04-01), None
patent: WO 00/46215 (2000-08-01), None
patent: WO 00/48603 (2000-08-01), None

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Benzazepinone alpha vintegrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzazepinone alpha vintegrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzazepinone alpha vintegrin receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3524801

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.